High dose cytarabine induced myopericarditis: When the heart debilitates but the fight against cancer must be strong
DOI:
https://doi.org/10.17533/udea.iatreia.140Keywords:
cytarabine, myocarditis, pericarditisAbstract
Knowledge about cytarabine induced cardiotoxicity is scarce. We present the clinical case of a 51-year-old patient with past medical history of Acute Myeloid Leukemia managed with high doses of cytarabine and who developed acute myopericarditis as a complication. After support management in intensive care unit, specific cardioprotective heart failure therapy was started and, due to the high possibility of requiring high doses of cytarabine in subsequent oncological management, therapy with Non-Steroidal Anti-inflammatory drugs and colchicine was given to reduce the risk of myopericarditis recurrence. We present the clinical case and a diagnostic strategy for patients with high doses of cytarabine and pericardial and myocardial involvement.
Downloads
References
(1) Yeh ET, Tong AT, Lenihan DJ, Yusuf SW, Swafford J, Champion C, et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation. 2004 Jun 29;109(25):3122-31. DOI 10.1161/01.CIR.0000133187.74800.B9.
(2) Reykdal S, Sham R, Kouides P. Cytarabine-induced pericarditis: A case report and review of the literature of the cardio-pulmonary complications of cytarabine therapy. Leuk Res. 1995 Feb 1;19(2):141–4. DOI 10.1016/0145-2126(94)00123-R.
(3) Baumann S, Huseynov A, Goranova D, Faust M, Behnes M, Nolte F, et al. Takotsubo cardiomyopathy after systemic consolidation therapy with high-dose intravenous cytarabine in a patient with acute myeloid leukemia. Oncol Res Treat. 2014;37(9):487-90. DOI 10.1159/000365536.
(4) Reese ND, Schiller GJ. High-dose cytarabine (HD araC) in the treatment of leukemias: a review. Curr Hematol Malig Rep. 2013 Jun;8(2):141-8. DOI 10.1007/s11899-013-0156-3.
(5) Saultz J, Garzon R. Acute Myeloid Leukemia: A Concise Review. J Clin Med. 2016 Mar 5;5(3):33. DOI 10.3390/jcm5030033.
(6) López-Fernández T, Martín García A, Santaballa Beltrán A, Montero Luis Á, García Sanz R, Mazón Ramos P, et al. Cardio-Onco-Hematology in Clinical Practice. Position Paper and Recommendations. Rev Esp Cardiol. 2017 Jun 1;70(6):474–86. DOI 10.1016/j.recesp.2016.12.021.
(7) Madias JE. Is Takotsubo syndrome in patients receiving chemotherapy drug-specific? World J Clin Cases. 2015;3(2):204–5. DOI 10.12998/wjcc.v3.i2.204.
(8) Goel S, Sharma A, Garg A, Chandra A, Shetty V. Chemotherapy induced Takotsubo cardiomyopathy. World J Clin Cases. 2014 Oct 16;2(10):565-8. DOI 10.12998/wjcc.v2.i10.565.
(9) Yang X, Liu W, Lyons A, Song Z, Zhai S, Hu K. Pericarditis associated with cytarabine therapy for acute myelocytic leukemia: a case report. Eur J Clin Pharmacol. 2018 Feb 1;74(2):181–2. DOI 10.1007/s00228-017-2355-7.
(10) Pai VB, Nahata MC. Cardiotoxicity of Chemotherapeutic Agents. Drug Saf. 2000 Jan 1;22(4):263–302. DOI 10.2165/00002018-200022040-00002.
(11) Gähler A, Hitz F, Hess U, Cerny T. Acute pericarditis and pleural effusion complicating cytarabine chemotherapy. Onkologie. 2003;26(4):348–50. DOI 10.1159/000072094.
(12) Wang L, Tan TC, Halpern EF, Neilan TG, Francis SA, Picard MH, et al. Major Cardiac Events and the Value of Echocardiographic Evaluation in Patients Receiving Anthracycline-Based Chemotherapy. Am J Cardiol. 2015 Aug 1 ;116(3):442–6. DOI 10.1016/j.amjcard. 2015.04.064.
(13) Herrmann J, Lerman A, Sandhu NP, Villarraga HR, Mulvagh SL, Kohli M. Evaluation and management of patients with heart disease and cancer: cardio-oncology. Mayo Clin Proc. 2014 Sep;89(9):1287-306. DOI 10.1016/j.mayocp.2014.05.013.
(14) Adler Y, Charron P, Imazio M, Badano L, Barón-Esquivias G, Bogaert J, et al. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC)Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2015 Nov 7;36(42):2921-64. DOI 10.1093/eurheartj/ehv318.
(15) Ghadri JR, Wittstein IS, Prasad A, Sharkey S, Dote K, Akashi YJ, et al. International Expert Consensus Document on Takotsubo Syndrome (Part I): Clinical Characteristics, Diagnostic Criteria, and Pathophysiology. Eur Heart J. 2018 Jun 7;39(22):2032-2046. DOI 10.1093/eurheartj/ehy076.
(16) Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni CA, Veglia F, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015 Jun 2;131(22):1981-8. DOI 10.1161/CIRCULATIONAHA.114.013777.
(17) Velásquez CA, González M, García-Orjuela MG, Jaramillo N. Radiation induced heart disease. Colomb. Cardiol. 2018;25(1):74-9. DOI 10.1016/j.rccar.2017.06.004.
(18) Plana JC. La quimioterapia y el corazón. Rev Esp Cardiol. 2011 May 1;64(5):409–15. DOI 10.1016/j.recesp.2010.12.013.
(19) López-Fernández T, Thavendiranathan P. Emerging Cardiac Imaging Modalities for the Early Detection of Cardiotoxicity Due to Anticancer Therapies. Rev Esp Cardiol. 2017;70(6):487-95. DOI 10.1016/j.recesp.2016.12.027.
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Universidad de Antioquia
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Papers published in the journal are available for use under the Creative Commons license, specifically Attribution-NonCommercial-ShareAlike 4.0 International.
The papers must be unpublished and sent exclusively to the Journal Iatreia; the author uploading the contribution is required to submit two fully completed formats: article submission and authorship responsibility.
